Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Involvement of E. faecalis in alcoholic hepatitis
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    • IBS Diagnosis Check List
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Involvement of E. faecalis in alcoholic hepatitis

Involvement of E. faecalis in alcoholic hepatitis

The gut bacterium E. faecalis migrates to the liver in the presence of alcohol and can produce a toxin that aggravates alcoholic hepatitis. A bacteriophage specifically targeting this bacterium eliminates inflammation and hepatic lesions.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    • IBS Diagnosis Check List
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 04 February 2020
Updated 30 September 2021

 

Alcoholic hepatitis is the most severe form of alcoholic liver disease and is associated with a mortality rate of 20 to 40% within 1 to 6 months. Although it is known that the gut microbiota can promote ethanol-induced liver diseases in mice, the microbial factors responsible for this process remain poorly understood. Hence the interest in the results published in Nature on the role of the microbiota in transmission and progression of this disease.

Cytolysin-secreting E. faecalis

The research shows that patients with alcoholic hepatitis exhibit a specific fecal microbial composition, namely having 2,700 times more Enterococcus faecalis, a bacterium found in the stools of 80% of patients. However, certain “cytolytic” types of these bacteria produce an endotoxin called cytolysin which acts against eukaryotic cells as well as against Gram-positive bacteria. The presence of cytolytic E. faecalis bacteria seems to be correlated to the severity of the liver disease and patient mortality.

From cytolysin to hepatic lesions

Gavage of mice subjected to a high ethanol intake diet (or to a control isocaloric diet without ethanol), with either cytolytic or non-cytolytic strains of E. faecalis, confirmed that cytolytic E. faecalis induced more hepatic lesions, steatosis and inflammation, and led to a more rapid death. This bacterium was also found in the livers of all mice subjected to a regimen with alcohol, but not in the liver of the control mice, suggesting that ethanol is required for translocation of E. faecalis from the gut to the liver.

A protective bacteriophage

The researchers then studied the therapeutic effects of a bacteriophage targeting cytolytic E. faecalis in mice receiving gavage with strains of E. faecalis responsible for hepatic steatosis. The bacteriophages reduced cytolysin levels in the liver of the rodents and eliminated their ethanol-induced hepatic lesions. The researchers then studied mice colonized with bacteria from stools of patients with alcoholic hepatitis. Administration of bacteriophages suppressed the onset of hepatic lesions and steatosis, and led to a decrease in the content of Enterococcus.

A future treatment?

These results not only established a link between the cytolytic E. faecalis bacterium and the severity and mortality rate of alcoholic hepatitis, they also showed that a bacteriophage can target the bacterium specifically, and so provide an alternative to antibiotics. Nevertheless, clinical studies are still required to prove the validity of cytolysin as a biomarker in human subjects, and to confirm that bacteriophages represent a safe and effective therapeutic approach.

 

Sources

Duan Y, Llorente C, Lang S et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019 Nov;575(7783):505-511.

Tags
Alcoholic hepatitis E. faecalis Steatosis Bacteriophage Biomarker

en_view en_sources

    Created 04 February 2020
    Updated 30 September 2021

    About this article

    To know more about this topic.

    Content type

    News

    Continue reading

    News
    Photo: Antibiotic resistance is a web of several problems (HCPs)
    02.11.2022

    Antibiotic resistance is a web of several problems

    Read the article
    21.02.2022

    Phage therapy for multidrug-resistant infections?

    Read the article
    18.07.2022

    The urinary microbiota: towards a new prognostic tool for prostate cancer?

    Read the article
    30.04.2019

    The lingual microbiota, biomarker of pancreatic cancer?

    Read the article
    11.09.2020

    Severity-specific signature of gut microbiota in chronic kidney disease

    Read the article
    25.09.2020

    Obesity: fecal virome transplant on trial

    Read the article
    Actu PRO : Dépression : un diagnostic plus précis grâce au microbiote intestinal ?
    30.03.2021

    Depression: more accurate diagnosis thanks to the gut microbiota?

    Read the article
    09.07.2019

    Gut microbiota is involved in lung cancer

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    Microbiota 17 EN
    Check out our latest magazine
    The first 1000 days of life
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    Obesity: Is a bacterial fatty acid involved?
    15.05.2023

    Obesity: Is a bacterial fatty acid involved?

    Read the article
    Photo: Endométriose : une clé de sa progression au sein du microbiote intestinal
    09.05.2023

    Endometriosis: A key to its progression in the gut microbiota?

    Read the article
    Photo: Atténuer la dénutrition avec des biotiques ?
    26.04.2023

    Mitigating malnutrition with biotics?

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo